RVNC News Alert Revance Therapeutics Inc. (RVNC) 16.65 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Revance Therapeutics Inc. (RVNC) 16.65 $RVNC

Revance Therapeutics Added to NASDAQ Biotechnology Index
GlobeNewswire - Thu Dec 18, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:^NBI), which will become effective upon market open on Monday, December 22, 2014.
IBB: 299.80 (+5.12), RVNC: 16.65 (+0.42)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 115.15 (+1.40), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), NKTR: 15.02 (+0.23), AGN: 210.12 (+0.95), IPXL: 31.32 (+0.26), ALDR: 25.67 (+0.43), QCOR: 93.60 (+1.52), MRK: 57.46 (+0.25), TSPT: 1.70 (-0.04), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07)

Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 104.59 (+0.31), RVNC: 16.65 (+0.42), CLTX: 4.70 (-0.20), GSK: 42.85 (+0.11), NKTR: 15.02 (+0.23), NVS: 93.91 (+0.66)

Revance Therapeutics, Inc. Announces Participation in 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Thu Nov 20, 6:20PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that its management is scheduled to participate in the 26 Annual Piper Jaffray Healthcare Conference.
RVNC: 16.65 (+0.42)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 11:48AM CST

IMDZ: 34.96 (+0.78), VTNR: 3.32 (-0.08), CYBR: 41.60 (+0.59), LJPC: 16.35 (-0.10), ZAZA: 3.20 (+0.70), XPLR: 6.60 (+0.06), FUEL: 17.08 (-0.12), NADL: 1.68 (-0.08), DWA: 22.72 (+0.05), CZR: 15.44 (+0.20), RCAP: 11.23 (+0.26), AMTX: 6.25 (-0.25), FLML: 17.01 (-0.98), AMOT: 23.01 (+0.35), RVNC: 16.65 (+0.42), LOCM: 1.15 (+0.03), JGW: 10.70 (+0.04), ICLD: 3.00 (-0.02), VPCO: 1.30 (-0.01), CSH: 22.16 (-0.46)

Revance set for gap down at the open
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:10AM CST

RVNC: 16.65 (+0.42)

Revance Therapeutics' (RVNC) CEO Dan Browne on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 7:33PM CST

RVNC: 16.65 (+0.42)

Revance Therapeutics beats by $0.09
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:20PM CST

RVNC: 16.65 (+0.42)

Revance Therapeutics Releases Third Quarter 2014 Results
GlobeNewswire - Wed Nov 12, 3:03PM CST
- Confirmation of Plans to Initiate Phase 2 Active Comparator Study for RT002 in 2014 -
RVNC: 16.65 (+0.42)

5 Earnings Short-Squeeze Plays: Weibo, Kohl's and More
at The Street - Wed Nov 12, 12:02PM CST
Sometimes the stock is going to be in such high demand that you risk missing a lot of the move by waiting.
KSS: 60.46 (-1.08), WB: 14.75 (-0.03), AMAT: 25.25 (-0.15), SBH: 30.89 (-0.29), RVNC: 16.65 (+0.42)

Revance Therapeutics, Inc. Announces Participation in Credit Suisse 2014 Healthcare Conference
GlobeNewswire - Tue Nov 04, 3:10PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that its management is scheduled to participate in the Credit Suisse 2014 Healthcare Conference in Phoenix, Arizona.
RVNC: 16.65 (+0.42)

Botulinum Toxin - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qw6vx2/botulinum_toxin) has announced the addition of the "Botulinum Toxin - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: - Cosmetic Applications - Therapeutic Applications The report profiles 19 companies including many key and niche players such as: - Allergan, Inc. - Ipsen Group - Medy-Tox Incorporated - Mentor Corporation - Merz Pharma GmbH & Co. KGaA - Metabiologics, Inc. - Revance Therapeutics, Inc. - US WorldMeds Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competition 3. Market Trends & Issues 4. Product/Industry Dynamics 5. Product Overview 6. Research Breakthroughs 7. Product Introductions/Approvals 8. Recent Industry Activity 9. Focus On Select Global Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 19 (including Divisions/Subsidiaries - 23) - The United States (9) - Japan (2) - Europe (6) - -France (1) - - Germany (1) - - The United Kingdom (3) - - Rest of Europe (1) - Asia-Pacific (Excluding Japan) (6) For more information visit http://www.researchandmarkets.com/research/qw...inum_toxin
AGN: 210.12 (+0.95), RVNC: 16.65 (+0.42)

Revance Therapeutics to Release Third Quarter 2014 Financial Results and Host Conference Call on Wednesday, November 12, 2014
GlobeNewswire - Wed Oct 29, 3:10PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today that the Company will release third quarter 2014 financial results on Wednesday, November 12, 2014 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and clinical update.
RVNC: 16.65 (+0.42)

Revance Therapeutics Provides Update on RT001 Clinical Program for the Lead Indication for Crow's Feet Lines
GlobeNewswire - Wed Oct 01, 3:01PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company has initiated a study to confirm this quarter the successful transfer of production of the topical RT001 drug product to Revance's U.S. commercial manufacturing facility. Following successful confirmation of this transfer, Revance plans to initiate its first U.S. Phase 3 RT001 pivotal study for the treatment of lateral canthal (crow's feet) lines, with results now anticipated during the first quarter of 2015. Previously, Revance expected to report results from the first U.S. Phase 3 pivotal study by the end of 2014.
RVNC: 16.65 (+0.42)

Global Axillary Hyperhidrosis Therapeutics Pipeline Review 2014 - 6 Companies & 8 Drug Profiles
M2 - Wed Sep 24, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xtbgmp/axillary) has announced the addition of the "Axillary Hyperhidrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Axillary Hyperhidrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Axillary Hyperhidrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Axillary Hyperhidrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Axillary Hyperhidrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Axillary Hyperhidrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Actavis plc - Revance Therapeutics, Inc. - TheraVida, Inc. - Brickell Biotech, Inc. - Dermira Inc. Drug Profiles - oxybutynin hydrochloride - RT-001 - solifenacin - ANT-1403 - onabotulinumtoxin A - DRM-04 - umeclidinium bromide - BBI-4000 For more information visit http://www.researchandmarkets.com/research/xtbgmp/axillary
DERM: 19.65 (+0.38), RVNC: 16.65 (+0.42), GSK: 42.85 (+0.11)

Revance Therapeutics names Azita Nejad as VP of Quality
M2 - Tue Sep 23, 4:37AM CDT
Biopharmaceutical company Revance Therapeutics (NasdaqGM :RVNC) revealed on Monday the appointment of Azita Nejad as vice president of Quality.
RVNC: 16.65 (+0.42)

Revance Therapeutics Announces the Appointment of Azita Nejad as Vice President of Quality
GlobeNewswire - Mon Sep 22, 3:46PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced Azita Nejad has been named its Vice President of Quality. In connection with her employment, the Compensation Committee of the Revance Board of Directors granted an inducement award pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
RVNC: 16.65 (+0.42)

Global Migraine Drug Forecast and Market Analysis to 2023 - A Potential $3.7 Billion Market
M2 - Thu Sep 11, 4:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qmmg2/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023" report to their offering. The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. Key Findings - The main driver of the expansion of the migraine market will be the continuous use of Botox for chronic migraine. The introduction of reformulations of mature products as well as new classes of therapies will further increase the market size. - The biggest barrier for the introduction of new therapies will be patent expirations of the majority of the drugs marketed for migraine, which have resulted in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period. - The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5q...harmapoint
AGN: 210.12 (+0.95), RDHL: 12.22 (-0.13), MRK: 57.46 (+0.25), RVNC: 16.65 (+0.42), GSK: 42.85 (+0.11)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Why Lear’s PACE Award Matters Beyond Seat Warmers Today

Updated Category News Views 111

Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 95

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 104

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 210

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 92

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Condo Downsizing Demands More Than a Price Check Today

Updated Category News Views 58

A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...

Continue Reading
BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 152

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 135

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Zoomcar's November 23 Report Puts Execution on Trial

Updated Category News Views 55

A Date on the Board, Not a Verdict November 23 is when Zoomcar finally has to put some fresh numbers beside the story. The Bengaluru-based peer-to-peer car-sharing marketplace says it will release second-quarter fiscal 2027 financial and operating results that Monday, covering the quarter ended September 30, 2026. Management also plans a live webcast at 8:00 a.m. Eastern...

Continue Reading

Top 5 Most Recently Viewed Articles

Main Street Capital Reports Impressive Q2 2025 Financials

Updated Category News Views 326

Main Street's Second Quarter 2025 Financial Performance Main Street Capital Corporation (NYSE: MAIN) recently disclosed its remarkable financial results for the second quarter of 2025. The company reported a net investment income of $88.2 million, which translates to approximately $0.99 per share. Additionally, the distributable net investment income stood at $94.3...

Continue Reading
argenx's Q1 2025 Growth: VYVGART Performance Shines Brightly

Updated Category News Views 463

Q1 2025 Financial Results Unveiled by argenx argenx SE, listed on both Nasdaq and Euronext as ARGX, is making waves in the biotech industry with its recent announcement of first-quarter financial results and a comprehensive business update. CEO Tim Van Hauwermeiren expressed enthusiasm regarding the company's trajectory, focusing on their ambitious "Vision 2030"—a...

Continue Reading
Pennsylvania's Resilient Housing Market: An Overview of Trends

Updated Category News Views 135

Pennsylvania Housing Market Shows Notable Resilience The latest data on the housing market in Pennsylvania highlights an encouraging trend, as home prices have experienced a remarkable increase of 6.5% over the past year. This consistent appreciation indicates a vigorous market, even in the face of fluctuating economic conditions. Median Home Prices Reach New Heights In...

Continue Reading
Yum China's Strategy Bolstered by Pizza Hut Buy

Updated Category News Views 129

Yum China's Bold Step Forward Here's a twist in the fast-food market worth chewing on: Yum China has wrapped up its $1.2 billion acquisition of the Pizza Hut brand in Mainland China from Yum! Brands. It's like snagging the keys to a long-coveted car after being the chauffeur for decades. Strategic Flexibility and Margin Growth What's at play? Well, Joey Wat, CEO of Yum...

Continue Reading
Insightful Overview of NCC Group plc's Recent Trading Activity

Updated Category News Views 88

Understanding Recent Trading Activities of NCC Group plc In the fast-paced world of finance, keeping an eye on trading activities can offer invaluable insights. One company that has recently been under the spotlight is NCC Group plc. The trading revelations come from public disclosures made under Rule 8.5, indicating vital movements in their securities. Key Information...

Continue Reading